Compare United States Brent Oil Fund LP (BNO) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Brent Oil Fund LP vs Novo Nordisk A/S — how do they compare? United States Brent Oil Fund LP trades at $46.76, while Novo Nordisk A/S trades at $50.27 (market cap $214.94B). The key difference: Novo Nordisk A/S pays a 3.67% dividend while United States Brent Oil Fund LP pays none, and United States Brent Oil Fund LP is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| BNO | NVO | |
|---|---|---|
Sector | Commodities - Energy | Health |
52-Week High | $60.13 | $71.70 |
52-Week Low | $27.20 | $35.29 |
Market Cap | — | $214.94B |
Enterprise Value | — | $233.91B |
Dividend Yield | — | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNO, a US-listed oil-focused stock, trades at $46.00, up 9.13% on the day, driven by escalating Middle East tensions that have pushed crude prices to one-month highs. Technical indicators show a bullish trend with strong moving average support, though the 6-day RSI at 86 suggests overbought conditions. Recent news highlights supply risks from U.S.-Iran hostilities, including blockades and strikes, which are boosting energy sector sentiment and driving volatility.
The outlook for BNO remains heavily tied to geopolitical developments and oil price momentum. Upside potential exists if supply disruptions persist, but risks include rapid de-escalation or demand weakness. Investors should weigh the stock's sensitivity to crude fluctuations against current bullish technical and sentiment signals.
Novo Nordisk (NVO) trades at $49.28, down 0.4% on the day, with strong technical momentum indicated by bullish moving averages and a neutral RSI near 63. The company demonstrates robust fundamentals with a P/E of 11.83, net income margin of 37.2%, and consistent earnings beats in recent quarters. Recent news highlights competitive strength in GLP-1 drugs, including Wegovy pill adoption outpacing Eli Lilly's offering.
Outlook remains positive given analyst consensus of 57.9% buy ratings and intrinsic value estimates near $90, though risks include prescription slowdown concerns and rising debt-to-asset ratios. The stock presents a growth opportunity in pharmaceuticals with manageable near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About United States Brent Oil Fund LP
BNO is a commodity ETF that tracks the daily price of Brent crude oil futures. It provides exposure to the international oil benchmark, which often trades at a premium to the U.S. WTI benchmark, and is primarily used for short-term trading due to roll costs.
Read more on BNO →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
